$0.56 -0.00 (-0.88%)

Century Therapeutics, Inc. Common Stock (IPSC)

Century Therapeutics, Inc. (IPSC) is a biotechnology company focused on developing allogeneic cell therapies for solid tumors and hematologic cancers. Leveraging its proprietary platform, Century aims to create off-the-shelf, living medicines using induced pluripotent stem cell (iPSC) technology to address unmet medical needs in cancer treatment.

🚫 Century Therapeutics, Inc. Common Stock does not pay dividends

Company News

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc. • Century Therapeutics • August 22, 2025

Century Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, with an on-demand webcast available and investor meetings scheduled.

5 Analysts Assess Century Therapeutics: What You Need To Know
Benzinga • Benzinga Insights • June 4, 2024

Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bu...

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 9, 2024

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
MarketWatch • MarketWatch • January 6, 2024

A more selective small-cap index has consistently outperformed the Russell 2000

How These Acquisitions Are Changing the Outlook for Bristol Myers Squibb
The Motley Fool • [email protected] (Natalie Forbes) • July 21, 2022

The company is reshaping and expanding its oncology portfolio.